Table 3: Therapeutic data.
Parameters |
Workforce (n) |
Percentage (%) |
Trither |
|
|
2INTI + INI |
109 |
37.8 |
2INTI + INNTI |
112 |
38.9 |
2INTI + IP |
66 |
22.9 |
INTI + IP + INI |
1 |
0.3 |
Current tripple therapy |
|
|
2INTI + INI |
141 |
49.0 |
2INTI + INNTI |
42 |
14.5 |
2INTI + IP |
46 |
15.9 |
INTI + IP + INI |
2 |
0.7 |
No TAR |
57 |
19.7 |
Reason for change |
|
|
No change |
146 |
62.6 |
National unavailability |
68 |
29.2 |
New recommendations |
12 |
5.2 |
Therapeutic failure |
2 |
0.8 |
Intolerance |
3 |
1.3 |
Adaptation to weight and age |
2 |
0.9 |
Reasons for delayed treatment |
|
|
Pre-therapeutic assessment pending |
58 |
79.4 |
Out of sight |
3 |
4.1 |
Out of stock |
2 |
2.8 |
Anti-TB treatment |
9 |
12.3 |
Anti TB treatment + Out of sight |
1 |
1.4 |